These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 11574780

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.
    Sissi C, Moro S, Richter S, Gatto B, Menta E, Spinelli S, Krapcho AP, Zunino F, Palumbo M.
    Mol Pharmacol; 2001 Jan; 59(1):96-103. PubMed ID: 11125029
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-Drug Research (CESAR).
    Hofheinz RD, Porta C, Hartung G, Santoro A, Hanauske AR, Kutz K, Stern A, Barbieri P, Verdi E, Hehlmann R, Hochhaus A.
    Invest New Drugs; 2005 Aug; 23(4):363-8. PubMed ID: 16012796
    [Abstract] [Full Text] [Related]

  • 11. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.
    Pratesi G, Perego P, Polizzi D, Righetti SC, Supino R, Caserini C, Manzotti C, Giuliani FC, Pezzoni G, Tognella S, Spinelli S, Farrell N, Zunino F.
    Br J Cancer; 1999 Aug; 80(12):1912-9. PubMed ID: 10471039
    [Abstract] [Full Text] [Related]

  • 12. The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane.
    Hasinoff BB, Tran KT.
    J Inorg Biochem; 1999 Aug; 77(3-4):257-9. PubMed ID: 10643663
    [Abstract] [Full Text] [Related]

  • 13. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.
    Leopold WR, Nelson JM, Plowman J, Jackson RC.
    Cancer Res; 1985 Nov; 45(11 Pt 1):5532-9. PubMed ID: 4053027
    [Abstract] [Full Text] [Related]

  • 14. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S, Almasan A.
    Cancer Res; 2003 Aug 01; 63(15):4713-23. PubMed ID: 12907654
    [Abstract] [Full Text] [Related]

  • 15. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.
    Pratesi G, De Cesare M, Caserini C, Perego P, Dal Bo L, Polizzi D, Supino R, Bigioni M, Manzini S, Iafrate E, Salvatore C, Casazza A, Arcamone F, Zunino F.
    Clin Cancer Res; 1998 Nov 01; 4(11):2833-9. PubMed ID: 9829750
    [Abstract] [Full Text] [Related]

  • 16. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A.
    J Cell Physiol; 2007 May 01; 211(2):533-43. PubMed ID: 17192846
    [Abstract] [Full Text] [Related]

  • 17. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G, De Cesare M, Carenini N, Perego P, Righetti SC, Cucco C, Merlini L, Pisano C, Penco S, Carminati P, Vesci L, Zunino F.
    Clin Cancer Res; 2002 Dec 01; 8(12):3904-9. PubMed ID: 12473606
    [Abstract] [Full Text] [Related]

  • 18. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
    Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D, Cuccuru G, Bombardelli E, Zunino F.
    Clin Cancer Res; 2002 Aug 01; 8(8):2647-54. PubMed ID: 12171897
    [Abstract] [Full Text] [Related]

  • 19. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.
    El-Zawahry A, McKillop J, Voelkel-Johnson C.
    BMC Cancer; 2005 Jan 07; 5():2. PubMed ID: 15638938
    [Abstract] [Full Text] [Related]

  • 20. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.
    Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H.
    Oncogene; 2003 Jul 31; 22(31):4851-9. PubMed ID: 12894226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.